Leukemia
Phase II
Accepting Patients
nct/study# NCT04093570 / ASTX727-06
An Open-Label, Multicenter, Extension Study For Subjects Who Participated In Prior Clinical Studies Of ASTX727 (Standard Dose)
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT04310592 / CYNK-001-AML-001
A Phase I Multi-Dose Study Of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) In Adults With Actively Diagnosed Primary Or Secondary Acute Myeloid Leukemia (AML) In Morphologic Complete Remission With Minimal Residual Disease (MRD)
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT03165734 / PAC203
A Randomized, Controlled Phase 3 Study Of Pacritinib Versus Physician’s Choice In Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/Ìl)(PACIFICA)
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NA / COMPASSIONATE-USE-PACRITINIB
Individual Patient Supply Of Oral Pacritinib In A Patient With Thrombocytopenia And Primary Myelofibrosis.
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT03915379 / JNJ-67571244-AML-1001
A Phase 1, First-In-Human, Dose Escalation Study Of JNJ-67571244 (Bispecific Antibody Targeting CD33 And CD3) In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT04075747 / JZP025-101
V-FAST: A Phase 1b Master Trial To Investigate CPX-351 Combined With Various Targeted Agents In Subjects With Previously Untreated Acute Myeloid Leukemia
Learn More
